Effectiveness and safety of rivaroxaban versus warfarin in obese nonvalvular atrial fibrillation patients: analysis of electronic health record data
Olivia S. Costa, Jan Beyer‐Westendorf, Veronica Ashton, Dejan Milentijevic, Kenneth Todd Moore, Thomas J. Bunz, Craig I Coleman
Abstract
Among obese NVAF patients, prescription of rivaroxaban was associated with a reduced risk of SSE and major bleeding compared to warfarin, which remained consistent across BMI classes.
Topics & Concepts
MedicineRivaroxabanAtrial fibrillationWarfarinElectronic health recordInternal medicineHealth recordsCardiologyHealth careEconomic growthEconomicsAtrial Fibrillation Management and OutcomesVenous Thromboembolism Diagnosis and ManagementBlood Pressure and Hypertension Studies